Emergent BioSolutions Signs Agreement to be U.S. Manufacturing Partner for Johnson & Johnson’s Lead Vaccine Candidate for COVID-19
Emergent will provide contract development and manufacturing services to support Johnson & Johnson’s commitment of one billion doses of vaccine for worldwide emergency pandemic use Agreement...
Emergent BioSolutions Appoints Dr. Karen L. Smith as Chief Medical Officer
GAITHERSBURG, Md. , April 21, 2020 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) today announced the appointment of Dr. Karen L. Smith , M.D., Ph.D. as chief medical officer with...
Emergent BioSolutions to Release First Quarter 2020 Financial Results and Conduct Conference Call on April 30, 2020
GAITHERSBURG, Md. , April 16, 2020 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, April 30, 2020 at 5:00 pm (Eastern Time) to discuss the...
Emergent BioSolutions Appoints Nina DeLorenzo as Senior Vice President of Global Public Affairs
GAITHERSBURG, Md. , April 06, 2020 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) today announced the appointment of Nina DeLorenzo to the position of senior vice president for...
Emergent BioSolutions Partners with U.S. Government for Comprehensive Response to Expedite Development of Plasma-Derived Therapy for COVID-19
BARDA to provide $14.5 million in funding to support development of COVID-Human Immune Globulin (COVID-HIG), a human plasma-derived therapy candidate being developed as a potential treatment for...
Emergent BioSolutions Signs Agreement with Novavax to Manufacture NanoFlu™
CDMO agreement for NanoFlu to support pathway to licensure Expanded collaboration now includes NanoFlu and COVID-19 vaccine candidate GAITHERSBURG, Md. , March 31, 2020 (GLOBE NEWSWIRE) —...
Emergent BioSolutions Signs Development and Manufacturing Agreement with Vaxart for their Experimental Oral Vaccine Candidate for Coronavirus Disease
GAITHERSBURG, Md. , March 18, 2020 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has entered into an agreement with Vaxart, Inc. (Nasdaq: VXRT), a...
Emergent BioSolutions Initiates Development of Plasma-Derived Product Candidates for the Treatment and Prevention of Coronavirus Disease
Human polyclonal hyperimmune with antibodies to SARS-CoV-2 (COVID-HIG) being developed as a potential treatment for severe hospitalized patients and protection for at-risk individuals Equine-derived...
Emergent BioSolutions Signs Development and Manufacturing Agreement With Novavax for Experimental Vaccine Candidate for Coronavirus Disease
GAITHERSBURG, Md. , March 10, 2020 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has entered into an agreement with Novavax, Inc. (NASDAQ:NVAX) whereby...
Emergent BioSolutions Reports Financial Results for Fourth Quarter and Full Year 2019
GAITHERSBURG, Md. , Feb. 20, 2020 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) reported financial results for the quarter and year ended December 31, 2019 . FINANCIAL HIGHLIGHTS...
Emergent BioSolutions to Release Fourth Quarter and Full Year 2019 Financial Results and Conduct a Conference Call on February 20, 2020
GAITHERSBURG, Md. , Feb. 03, 2020 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, February 20, 2020 at 5:00 pm (Eastern Time) to discuss the...
Emergent BioSolutions Receives Positive CHMP Opinion for Vaxchora; Anticipates Near-Term Approval by European Medicines Agency
GAITHERSBURG, Md. , Jan. 31, 2020 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE:EBS) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European...